TNF and neoplasm: To further confirm the modifying effects of TNF-α promoter variant on risk of HPV16-associated SCCOP, we assessed the association of the combined risk genotypes with HPV16-positive SCCOP patients based on tumor HPV16 status instead of HPV16 serology.